In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Centessa Pharmaceuticals, with a price target of $38.00. The company’s shares closed yesterday at $23.05.Elevate Your...
SAURABH SAHA, the Chief Executive Officer of $CNTA ($CNTA), sold 1,671 shares of the company on 11-22-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.3%...
Centessa Pharmaceuticals released strong results in Phase 1 trials and now Wall Street analysts are buzzing over the stock.
/PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they can trust, today announced that Gordon...
/PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Centessa...
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Centessa Pharmaceuticals plc (“Centessa” or the “Company”) (NASDAQ:...
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 28, 2022 to file lead plaintiff applications...
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Centessa Pharmaceuticals Plc (“Centessa” or the...
/PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Centessa Pharmaceuticals plc (NASDAQ:...
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Centessa Pharmaceuticals plc ("Centessa" or the "Company") (NASDAQ:...